BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

915 related articles for article (PubMed ID: 29717162)

  • 1. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.
    Zhang Z; Xu X; Tian W; Jiang R; Lu Y; Sun Q; Fu R; He Q; Wang J; Liu Y; Yu H; Sun B
    J Hepatol; 2020 May; 72(5):976-989. PubMed ID: 31857195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
    Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
    Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in hepatic lipid species of age-matched male mice fed a methionine-choline-deficient diet and housed in different animal facilities.
    Rein-Fischboeck L; Haberl EM; Pohl R; Feder S; Liebisch G; Krautbauer S; Buechler C
    Lipids Health Dis; 2019 Sep; 18(1):172. PubMed ID: 31521175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDF15 as a central mediator for integrated stress response and a promising therapeutic molecule for metabolic disorders and NASH.
    Kim KH; Lee MS
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129834. PubMed ID: 33358864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIRT6 Protects Against Liver Fibrosis by Deacetylation and Suppression of SMAD3 in Hepatic Stellate Cells.
    Zhong X; Huang M; Kim HG; Zhang Y; Chowdhury K; Cai W; Saxena R; Schwabe RF; Liangpunsakul S; Dong XC
    Cell Mol Gastroenterol Hepatol; 2020; 10(2):341-364. PubMed ID: 32305562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Vsig4 attenuates macrophage-mediated hepatic inflammation and fibrosis in high fat diet (HFD)-induced mice.
    Li Y; Sun JP; Wang J; Lu WH; Xie LY; Lv J; Li HX; Yang SF
    Biochem Biophys Res Commun; 2019 Aug; 516(3):858-865. PubMed ID: 31266632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GDF11 induces mild hepatic fibrosis independent of metabolic health.
    Frohlich J; Kovacovicova K; Mazza T; Emma MR; Cabibi D; Foti M; Sobolewski C; Oben JA; Peyrou M; Villarroya F; Soresi M; Rezzani R; Cervello M; Bonomini F; Alisi A; Vinciguerra M
    Aging (Albany NY); 2020 Oct; 12(20):20024-20046. PubMed ID: 33126224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
    Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
    BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2.
    Lee EH; Lee JH; Kim DY; Lee YS; Jo Y; Dao T; Kim KE; Song DK; Seo JH; Seo YK; Seong JK; Moon C; Han E; Kim MK; Ryu S; Shin M; Roh GS; Jung HR; Osborne TF; Ryu D; Jeon TI; Im SS
    Exp Mol Med; 2024 Apr; 56(4):1001-1012. PubMed ID: 38622198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH).
    Lee JH; Oh JY; Kim SH; Oh IJ; Lee YH; Lee KW; Lee WH; Kim JH
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J; Schlerman F; Akare S; Wang J; McMahon J; Zhan Y; Syed J; He W; Zhang B; Martinez RV
    PLoS One; 2019; 14(12):e0226854. PubMed ID: 31891606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Stellate Cells in Hepatocellular Carcinoma Promote Tumor Growth Via Growth Differentiation Factor 15 Production.
    Myojin Y; Hikita H; Sugiyama M; Sasaki Y; Fukumoto K; Sakane S; Makino Y; Takemura N; Yamada R; Shigekawa M; Kodama T; Sakamori R; Kobayashi S; Tatsumi T; Suemizu H; Eguchi H; Kokudo N; Mizokami M; Takehara T
    Gastroenterology; 2021 Apr; 160(5):1741-1754.e16. PubMed ID: 33346004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
    Widjaja AA; Singh BK; Adami E; Viswanathan S; Dong J; D'Agostino GA; Ng B; Lim WW; Tan J; Paleja BS; Tripathi M; Lim SY; Shekeran SG; Chothani SP; Rabes A; Sombetzki M; Bruinstroop E; Min LP; Sinha RA; Albani S; Yen PM; Schafer S; Cook SA
    Gastroenterology; 2019 Sep; 157(3):777-792.e14. PubMed ID: 31078624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice.
    Du M; Wang X; Yuan L; Liu B; Mao X; Huang D; Yang L; Huang K; Zhang F; Wang Y; Luo X; Wang C; Peng J; Liang M; Huang D; Huang K
    J Hepatol; 2020 Dec; 73(6):1333-1346. PubMed ID: 32717288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic intermittent hypoxia accelerates liver fibrosis in rats with combined hypoxia and nonalcoholic steatohepatitis via angiogenesis rather than endoplasmic reticulum stress.
    Wu W; Li W; Wei J; Wang C; Yao Y; Zhu W; He W; Zhou W; Liu J
    Acta Biochim Biophys Sin (Shanghai); 2019 Feb; 51(2):159-167. PubMed ID: 30668625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
    Nakanishi K; Kaji K; Kitade M; Kubo T; Furukawa M; Saikawa S; Shimozato N; Sato S; Seki K; Kawaratani H; Moriya K; Namisaki T; Yoshiji H
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.